No Data
Ascentage Pharma Group International Files for Proposed US IPO
Ascentage Pharma (6855.HK) is about to go public in the United States, starting a new journey of value growth.
Since reaching its peak in 2021, the overall performance of the Biomedical Sector has been less than optimistic. Even with the overall market being lively this year, the Biomedical Sector has still significantly underperformed the Index.
Announcement highlights | A subsidiary of China Energy Engineering won an EPC general contracting project worth nearly 5.9 billion yuan; VESYNC received a premium of approximately 33.33% for privatization, and resumes trading today.
China Energy Engineering Corporation's subsidiary has won an EPC general contracting project worth nearly 5.9 billion yuan; SANXUN GROUP's sales in the first 11 months decreased by more than 60% year-on-year.
Hong Kong Stock Announcement to Explore | iFlytek Medical Technology's public offering received 3.66 times subscription, with a global net raised of approximately 0.507 billion Hong Kong dollars.
VESYNC (02148) received a privatization proposal from the acquirer VICTORY III CO., LTD through an agreement arrangement and will resume trading on December 30; ASCENTAGE-B (06855) plans to apply for listing American depositary shares on the Nasdaq Global Select Market (or Nasdaq).
ASCENTAGE-B (06855) intends to apply for listing American depositary shares on the Nasdaq Global Select Market (or Nasdaq).
ASCENTAGE-B (06855) released an announcement regarding the confidential submission to the securities commission of a proposal for an initial public offering...
Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.
Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.
Unlock the Full List
